Mutations cause protein folding defects that result in cellular misrouting of otherwise functional proteins. Such mutations are responsible for a wide range of disease states, especially among G-protein coupled receptors. Drugs which serve as chemical templates and promote the proper folding of these proteins are valuable therapeutic molecules since they return functional proteins to the proper site of action. Small molecules have been identified that are able to function as pharmacological chaperones or "pharmacoperones" and stabilize the correct conformations of their target proteins with high specificity. Most of these are also agonists or antagonists of the proteins of interest, complicating potential therapeutic use. This is due, in part, to the fact that the majority of these were discovered during high-throughput screening campaigns using assays designed to detect agonists and antagonists, rather than compounds which improve the trafficking of misrouted mutants. The assays described in this report are designed specifically to identify compounds which result in the reactivation and correct trafficking of misfolded gonadotropin releasing hormone receptor and vasopressin type 2 receptor mutants, rather than those which act as agonists directly. The system reported is a generalizable approach amenable to use in automated (robotic) high-throughput screening efforts and can be used to identify compounds which affect protein conformation without necessarily acting as direct agonists or antagonists.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/B978-0-12-391862-8.00001-6 | DOI Listing |
Front Mol Neurosci
December 2024
Department of Surgery, University of Virginia, Charlottesville, VA, United States.
Introduction: Dysfunction of the enteric nervous system (ENS) is linked to a myriad of gastrointestinal (GI) disorders. Piezo1 is a mechanosensitive ion channel found throughout the GI tract, but its role in the ENS is largely unknown. We hypothesize that Piezo1 plays an important role in the growth and development of the ENS.
View Article and Find Full Text PDFTurk J Biol
October 2024
METU MEMS Center, Ankara, Turkiye.
Background/aim: No specific pharmacological treatment regimen for idiopathic pulmonary fibrosis (IPF) exists. Therefore, new antiinflammatory therapeutic strategies are needed. Cannabinoids (CBs), known for their inflammation-modulating and antifibrotic effects, may be potential medication candidates for treating IPF.
View Article and Find Full Text PDFJ Obstet Gynaecol India
December 2024
Nowrosjee Wadia Maternity Hospital, Mumbai, India.
Endometriosis affects about 10 percent women in the reproductive age group globally and approximately 42 million in India. Managing the patient's pain symptoms associated with endometriosis appears to be the cornerstone in endometriosis disease management. The ideal medical treatment in endometriosis would be suppressing estradiol enough to alleviate symptoms of endometriosis but maintain sufficient levels to mitigate hypoestrogenic side effects.
View Article and Find Full Text PDFCurr Top Med Chem
January 2025
School of Pharmacy & School of Biological and Food Engineering, Changzhou University, Changzhou, 213164, Jiangsu, PR China.
Transient receptor potential vanilloid (TRPV) channels are a member of the TRP superfamily, which consists of six proteins and is expressed in many neuronal and non-neuronal cells. Among them, TRPV1-4 are non-selective cation channels that are highly sensitive to temperature changes, while TRPV5-6 are channels that are highly selective to Ca2+. These cation channels have attracted great interest academically, especially from a pharmacological perspective.
View Article and Find Full Text PDFExpert Opin Ther Pat
January 2025
Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Kraków, Poland.
Introduction: Histamine H receptor antagonists/inverse agonists, since the discovery of histamine H receptor (HR), are important ligands in the search for new potential drugs. The most interesting are CNS diseases as these receptors are mainly there present.
Areas Covered: The current review covers patent applications/patents that were published during the last 6 years (October 2017 - December 2023).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!